Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
BMC Infect Dis
; 18(1): 357, 2018 07 31.
Article
en En
| MEDLINE
| ID: mdl-30064371
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
Inhibidores de Integrasa
/
Fármacos Anti-VIH
/
Síndrome de Lipodistrofia Asociada a VIH
/
Sustitución de Medicamentos
/
Rilpivirina
/
Lípidos
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2018
Tipo del documento:
Article